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Abstract: Informatics and computational design methods were used to create new molecules that could potentially bind antiapoptotic 
proteins, thus promoting death of cancer cells. Apoptosis is a cellular process that leads to the death of damaged cells. Its malfunction 
can cause cancer and poor response to conventional chemotherapy. After being activated by cellular stress signals, proapoptotic proteins 
bind antiapoptotic proteins, thus allowing apoptosis to go forward. An excess of antiapoptotic proteins can prevent apoptosis. Designed 
molecules that mimic the roles of proapoptotic proteins can promote the death of cancer cells. The goal of our study was to create new 
putative mimetics that could simultaneously bind several antiapoptotic proteins. Five new small molecules were designed that formed 
stable complexes with BCL-2, BCL-XL, and MCL-1 antiapoptotic proteins. These results are novel because, to our knowledge, there 
are not many, if any, small molecules known to bind all three proteins. Drug-likeness studies performed on the designed molecules, as 
well as previous experimental and preclinical studies on similar agents, strongly suggest that the designed molecules may indeed be 
promising drug candidates. All five molecules showed “drug-like” properties and had overall drug-likeness scores between 81% and 
96%. A single drug based on these mimetics should cost less and cause fewer side effects than a combination of drugs each aimed at a 
single protein. Computer-based molecular design promises to accelerate drug research by predicting potential effectiveness of designed 
molecules prior to laborious experiments and costly preclinical trials.
Keywords: cancer, anticancer drug research, apoptosis, small molecule mimeticsDalafave and Prisco
170  Cancer Informatics 2010:9
Introduction
Conventional  drug  design  techniques  are  based 
on  trial-and-error  testing  using  cells  or  animals. 
  High-throughput  screening  for  chemicals  with 
desired  bioactivities  requires  specialized  labs  that 
make the process costly. With a growing number of 
known experimental structures of target molecules, 
computational  methods  have  been  used  success-
fully  to  supplement  and  speed  up  drug  discovery. 
Computer-based  molecular  design  combines  meth-
ods of informatics, medicine, and biophysics. This 
  cross-disciplinary field has accelerated drug research 
by predicting the potential therapeutic effectiveness 
of designed molecules prior to laborious experiments 
and  costly  preclinical  trials.  In  addition,  computa-
tional modeling has led to discoveries of structures 
of novel small molecules. In this work, informatics 
and computational design were used to create and 
  evaluate  new  small  molecule  mimetics  that  could 
potentially promote death of   cancer cells.
Apoptosis  is  an  important  cellular  process  that 
causes death of damaged cells.1 Its malfunction can 
lead  to  cancer  development  and  poor  response  to 
conventional  chemotherapy.2    Cellular  proteins  from 
the BCL-2 family are crucial for apoptosis.3,4 Under-
standing their interactions is vital for anticancer drug 
design.5 Proteins from the BCL-2 family can be either 
prodeath (proapoptotic) or prosurvival (antiapoptotic). 
Antiapoptotic proteins, such as BCL-2, BCL-XL, and 
MCL-1, share homology in three to four conserved 
BH peptide domains (BH1, BH2, BH3, and BH4).6,7 
Proapoptotic proteins, such as BAX, BAK, BIM, BAD, 
and BID, share homology only in the BH3 domain.
Cellular  damage  stimulates  prodeath  stress  sig-
nals.  After  being  activated  by  the  stress  signals, 
proapoptotic proteins can bind antiapoptotic proteins, 
thus allowing apoptosis to proceed. Stress signals are 
sensed by the BH3-only proteins called “activators”, 
which  can  activate  proapoptotic  BAX  and  BAK 
proteins.8,9 This leads to the mitochondrial membrane 
deterioration10,11 and commits the cell to apoptosis. 
The, so called, “sensitizer” proteins allow apoptosis 
to proceed by preventing the binding of antiapoptotic 
proteins to activators.12 Propagation of death signals 
is hindered by antiapoptotic proteins.13 Antiapoptotic 
protein BCL-2 resists apoptosis mainly by binding 
activators, thus precluding their activation of BAX 
and BAK.14,15 Cancer cells can avoid death signals 
by overexpressing antiapoptotic proteins, inhibiting 
proapoptotic activators, or precluding BAX and BAK 
activation.16 These can also lead to poor chemotherapy 
response.17 Disabling of antiapoptotic proteins is often 
needed for apoptosis to proceed.16 BH3 mimetics are 
designed molecules that mimic the functions of BH3-
only proapoptotic cell proteins.18 The BH3 mimetics 
can help destroy cancer cells by inhibiting antiapop-
totic proteins and specifically targeting pathways that 
allow survival of cancer cells.19
Previously  designed  small  molecule  ABT-737 
[Protein Data Bank20 (PDB) entry: 2YXJ] allows BAX 
and BAK activation by binding BCL-2, BCL-XL, and 
BCL-W and disrupting their complexes with proapop-
totic proteins.21 ABT-737 was originally designed by 
combining  two  molecules  of  medium  affinities  to 
obtain one molecule of high affinity.4
Previous studies revealed that ABT-737 was deadly 
to many cancer cells.4 It was reported that it makes 
cells with overexpressed BCL-2 ready for apoptosis at 
a much higher degree than those with overexpressed 
BCL-XL, although their affinities for ABT-737 are 
similar.4 The reason for this is unclear, which sug-
gests that interactions of ABT-737 with these proteins 
are still not well understood. ABT-737 is an effective 
single agent in cancers with low or absent MCL-1.4 
However, ABT-737  is  not  efficient  in  cancer  cells 
with overexpressed MCL-1. Preclinical studies show 
that ABT-737 could easily induce apoptosis in many 
cancer cells if MCL-1 is eliminated or suppressed.22 
Using ABT-737 in combination with an agent that can 
target MCL-1 holds great clinical promise.
Obatoclax  is  a  designed  molecule  (ChemDB 
database23 compound ID (CID):16681698) that can 
supplement the activity of ABT-737. Although Oba-
toclax has a lower affinity than ABT-737 for BCL-2, 
BCL-XL, and BCL-W,24 it can successfully prevent 
MCL-1/BAK  binding.25  Another  small  molecule, 
Antimycin A, is able to suppress cancer growth if 
used at high concentrations.26 A combination of drugs 
targeting several antiapoptotic proteins may be nec-
essary to overcome resistance to apoptosis in some 
cancers.27,28 A designed molecule, ABT-702 (ChemDB 
database  CID:  3965212),  shows  anti-inflammatory 
actions in cells.29 To the best of our knowledge, ABT-
702 has not been studied for anticancer applications. 
Its complexes with BCL-2, BCL-XL, and MCL-1 are 
not known. However, using ABT-702 as a   starting small molecule mimetics
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  template,  we  were  able  to  design  new  potential 
mimetics that bonded BCL-2, BCL-XL, and MCL-1 
proteins and showed drug-likeness.
Computational studies of small molecule mimetics 
can be done using several commercial and open-access 
docking programs and servers, such as ArgusLab,30 
GOLD,31 AUTODOCK,32 and ZDOCK.33 Commercial 
GOLD docking program has been previously used to 
successfully study interactions between BCL-2 and 
several small molecules.34 It was found that the bind-
ing energies of stable complexes formed by BCL-2 
and  C33H35NO6S  and  C26H21NO6S  small  molecules 
were, respectively, −46.0 and −41.9 kJ/mol, qualita-
tively agreeing with experiments.34
Drugs based on mimetics that specifically target a 
single antiapoptotic protein can result in drug resis-
tance.  Conversely,  drugs  that  act  too  broadly  may 
damage  healthy  cells.  An  alternative  is  to  design 
drugs based on mimetics that bind two or three anti-
apoptotic molecules. Such a drug should have action 
broad enough to evade drug resistance, yet be specific 
enough to minimize damage to healthy tissue. The 
drug would likely be more cost-effective and cause 
fewer  side  effects  than  the  use  of  multiple  drugs, 
which each target an individual protein.
A promising drug candidate should be “  drug-like”, 
which means that it should have characteristics   similar 
to known drugs. Bioavailability, protein affinity, tox-
icity, transport, absorption, and metabolic stability of 
a compound depend on many factors. These factors 
include  the  compound’s  hydrophobicity,  electronic 
distribution,  hydrogen  bonding,  and  molecule  size 
and flexibility.
The  logarithm  of  octanol-water  partition  coeffi-
cient, logP, is recognized in drug design as a depend-
able gauge of the compound’s hydrophobicity. High 
logP values are related to low absorption. A logP value 
smaller than 5 indicates that a compound is likely to 
be easily absorbed by the organism.35 Another indi-
cator of drug-likeness is the logS value (solubility). 
A reasonable value for logS is around −4, which trans-
lates to 0.1 mmol/liter.35 Most commercially avail-
able drugs have logS values between −4 and −1.35,40 
  Molecular polar surface area (PSA) corresponds to 
the total surface area of polar atoms. PSA is a very 
valuable  indicator  of  molecular  transport  through 
membranes.36  PSA  is  used  to  predict  a    potential 
drug’s  absorption,  including  intestinal  absorption, 
  bioavailability, and blood-brain barrier penetration. 
A drug-like molecule should have a PSA value of less 
than 120 Å2.36
Most  commercially  available  drugs  have  molar 
masses of less than 500 g/mol. Molecules with higher 
masses are less likely to be absorbed and thus less 
likely to reach their target. The oral bioavailability of 
a drug can be predicted using the number of rotat-
able bonds, which measures molecular flexibility.37 
Oral bioavailability studies in rats (for over 1100 drug 
candidates)37 have indicated that compounds with 10 
or fewer rotatable bonds are highly likely to have 
good oral bioavailability. A relatively simple method 
that can help eliminate compounds that are not good 
drug candidates is Lipinski’s Rule of Five.38 The Rule 
states that most “drug-like” molecules have logP # 5, 
molar mass # 500 g/mol, 5 or fewer hydrogen bond 
donors, and 10 or fewer hydrogen bond acceptors. 
Molecules violating two or more of these rules may 
not be good drug candidates.
Our goal was to design new small molecule mimet-
ics that would be drug-like and could potentially bind 
all three BCL-2, BCL-XL, and MCL-1 proteins, thus 
allowing  apoptosis  to  proceed. The  findings  could 
facilitate the search for new drugs that are able to 




Three-dimensional  (3D)  experimentally  known 
structures of the antiapoptotic BCL-2, BCL-XL, and 
MCL-1  proteins  and  the  ABT-737  molecule  were 
obtained from the Protein Data Bank (PDB), entries 
2O22,  1PQ1,  2ROD,  and  2YXJ,  respectively. The 
structures of obatoclax (CID: 4905081) and ABT-702 
(CID: 3965212) were obtained from ChemDB online 
databases. ChemDB was searched for small molecules 
that were similar in structure to obatoclax, ABT-737, 
or ABT-702. Experimental 3D structures of 47 rel-
evant molecules were identified. Of these, 41 mol-
ecules were found to make either no stable poses or 
marginally stable poses with the BCL-2, BCL-XL, 
or  MCL-1  proteins.  The  remaining  six  molecules 
formed stable poses with at least one of the proteins, 
while only three of these formed stable poses with all 
three proteins. These three small molecules, as well 
as ABT-737 and ABT-702, were used as templates to Dalafave and Prisco
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design new putative BH3 mimetics that formed sta-
ble complexes with all three BCL-2, BCL-XL, and 
MCL-1 proteins and possessed drug-like properties.
Computer Tools
The Deep View39 and ArgusLab30 computer programs 
were used to design the new putative mimetics and 
study their interactions with the BCL-2, BCL-XL, 
and MCL-1 proteins. ArgusLab is a docking program 
that facilitates molecular building and computational 
drug design. To perform docking one first needs to 
define atoms that make up the ligand and the bind-
ing site of the protein where the ligand should bind. 
During docking calculations the program attempts to 
position the ligand into the binding site and reports 
on any stable poses that it finds. ArgusLab can also 
perform semiempirical geometry optimizations.
Deep View is a user friendly program that allows 
simultaneous studies of several molecules. It greatly 
facilitates the design of molecular models. The mol-
ecules can be overlaid to reveal structural alignments 
and allow comparisons of their binding sites. Intui-
tive graphic and menu tools in Deep View allow easy 
mutations of amino acids and visualization of atomic 
bonds. The program can also perform energy minimi-
zations. Lastly, good quality molecular images can be 
generated.
Two  open-source  programs,  OSIRIS  Property 
Explorer40 and Molinspiration41 were used to predict 
the drug-likeness of newly designed small molecules. 
The  programs  calculated  the  values  of  logP,  logS, 
PSA, and molar mass; the numbers of rotatable bonds, 
H-bond acceptors, and H-bond donors; as well as the 
drug-likeness and overall drug scores. OSIRIS Property 
Explorer also estimated the risks of side effects, such as 
mutagenicity or tumorigenicity. To calculate the overall 
drug score, OSIRIS combined logP, logS, molar mass, 
drug-likeness, and toxicity risks in a single number to 
predict the molecule’s overall drug potential.
Procedure employed
The 3D structures of BCL-2, BCL-XL, and MCL-1 
proteins were downloaded into the Deep View pro-
gram. Amino acids within 6 Å of the proteins’ BH3 
binding  sites  were  selected  for  molecular  building 
and docking studies in ArgusLab.
Experimentally  known  small  molecules  were 
docked  in  turn  to  BCL-2,  BCL-XL,  and  MCL-1 
  proteins. Docking was done using the ArgusLab GA 
dock function, along with the flexible setting where 
the twisting of molecular bonds was allowed. The sta-
bility of each docked pose was evaluated using Argus-
Lab energy calculations. Three of the experimentally 
known  molecules,  CID  18177004,  CID  11673546, 
and CID 11544167, formed stable complexes with all 
three proteins.
By systematically modifying and combining parts 
of the three molecules, ABT-702, and ABT-737, new 
small  molecules  were  designed  using  the  Molecule 
Builder function in ArgusLab. Atoms in the original 
molecules were systematically substituted or deleted. 
Some fragments were moved to a different site in the 
molecule or added from other molecules. The newly-
obtained molecules were then docked in turn to BCL-2, 
BCL-XL, and MCL-1. The molecules with the highest 
affinities were further modified. This procedure identi-
fied five newly designed small molecules that bonded 
all three antiapoptotic proteins and had promising drug-
like properties. The OSIRIS Property Explorer40 and 
Molinspiration41 were used to calculate drug-related 
properties for the five molecules as well as predict their 
drug-likenesses and potential side effects.
Results and Discussion
The binding energies of complexes formed by BCL-2, 
BCL-XL, and MCL-1 and the three small molecules 
originally identified in the ChemDB databases (CID 
11673546, CID 18177004, and CID 11544167) are 
shown in Table 1. More negative binding energies 
correspond to higher binding affinities.
Five new small molecules were designed from frag-
ments of the three original molecules, ABT-737, and 
ABT-702, by substitution, insertion, and/or deletion, 
as described in the Methodology section of this paper. 
Figure 1 shows the structures of the five designed 
small molecules. The binding energies of complexes 
Table 1. The binding energies of the stable poses formed 
by  BCL-2,  BCL-XL,  and  MCL-1  and  the  experimentally 









11673546 −38.7 −39.2 −36.3
18177004 −39.4 −34.4 −39.4
11544167 −40.4 −39.1 −37.2small molecule mimetics
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formed by the five designed molecules and BCL-2, 
BCL-XL and MCL-1 are given in Table 2.
Small molecule CID 11673546 was used as an ini-
tial template to design the C18H23N4 molecule. The new 
molecule had a high affinity for all three antiapoptotic 
proteins. As can be seen from Table 2, the energies of its 
stable complexes with BCL-2, BCL-XL, and MCL-1 
were −43.5, −43.1, and −50.2 kJ/mol, respectively. 
These energies are, respectively, 12%, 10%, and 39% 
more negative than for the protein complexes formed 
with the unmodified CID 11673546 molecule.
The  binding  energies  of  BCL-2,  BCL-XL,  and 
MCL-1complexes  with  the  designed  molecule 
C16H15N6 were −35.0, −34.7, and −41.9 kJ/mol, res-
pectively  (Table  2).  C16H15N6  formed  more  stable 
complexes with BCL-XL and MCL-1 then the origi-
nal molecule CID 11877004. Its binding energies with 
BCL-XL and MCL-1 became, respectively, about 1% 
and 6% more negative. Its binding energy with BCL-2 
became less negative by about 11%. However, while 
the original molecule was not drug-like, the designed 
C16H15N6 molecule scored high on all studied drug-
likeness criteria.
Complexes formed by the new molecule C14H15N3O 
and BCL-2, BCL-XL, and MCL-1 had binding ener-
gies of −40.5, −35.8, and −37.5 kJ/mol, respectively 
(Table 2). These energies were almost the same as for 
the original CID 11544167 molecule.   Nevertheless, 
the  designed  C14H15N3O  molecule  was  drug-like, 
whereas the original CID 11544167 was not.
Molecules C17H15N4 and C13H10N3 were designed 
from  fragments  of  ABT-737  and  ABT-702.  Both 
  molecules  formed  stable  complexes  with  all  three 
proteins. The binding energies resulting from dock-
ing  C17H15N4  to  BCL-2,  BCL-XL  and  MCL-1 
were  −35.3,−40.5,  and  −36.8  kJ/mol,  respectively 
(Table  2).  The  binding  energies  of  the  complexes 
between C13H10N3 and BCL-2, BCL-XL and MCL-1 
were −39.5, −33.5, and −36.3 kJ/mol, respectively 
(Table 2). The formation of the stable complexes of 
these two designed molecules and MCL-1 is espe-
cially  significant  since  the  original ABT-737  does 
not interact with MCL-1. In addition, to the best of 
our knowledge, complexes of ABT-702 and BCL-2, 
BCL-XL and MCL-1 are not known.
Some general features could be observed for all 
five designed molecules. They all contain the pyrrole 
ring, which seems to play an important role in their 
binding. It is noteworthy that pyrrole is used to derive 
certain compounds that are utilized by pharmaceuti-
cal industries for drug production. The polar surface 
areas (PSAs) of all five molecules are between about 
31 and 81 Å2, well below the “drug-likeness” cutoff 
of 120 Å2. In addition, their molar masses are less 
than about 303 g/mol. All of the five designed mol-
ecules have 6 or fewer rotatable bonds and H-bond 
acceptors, as well as 5 or fewer H-bond donors. All 
of these parameters have been shown to be reliable 
indicators of drug-likeness.35–37
Drug design entails devising small molecules that 
are complementary to the protein binding site.42 In 
general, protein binding sites display specificity and 
affinity toward certain ligands.43 
When bound to the small molecules designed in 
this study, the BCL-2, BCL-XL and MCL-1 proteins 
Table 2. The binding energies of complexes formed by BCL-2, BCL-XL and MCL-1 and the designed small molecules 
obtained via ArgusLab.










CID 11673546 C18h23n4 −43.5 −43.1 −50.2
CID 18177004 C16h15n6 −35.0 −34.7 −41.9
CID 11544167 C14h15n3O −40.5 −35.8 −37.5
ABT-737/ABT-702 C17h15n4 −35.3 −40.5 −36.8
ABT-737/ABT-702 C13h10n3 −39.5 −33.5 −36.3
Figure 1. structures of the five designed small molecules, from left to 
right: C18h23n4, C16h15n6, C14h15n3O, C17h15n4, and C13h10n3. Color code: 
C-yellow, n-pink, O-green, h-white.Dalafave and Prisco
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experienced  various  degrees  of  structural  changes 
when compared to their unbound states.
Day et al42 showed that Noxa and Puma bonded to a 
hydrophobic groove created by MCL-1 residues M212, 
V230, V234, T247 and F251. In our study, we identi-
fied MCL-1 binding site which included the above resi-
dues. All five of the designed molecules bonded within 
this site. Figure 2 shows MCL-1 binding groove with 
designed molecule C17H15N4. The Noxa- and Puma-
binding residues M212, V230, V234, T247, and F251 
are indicated as yellow spheres in Figure 2.
Experiments showed that all BH3 ligands caused 
similar  structural  modifications  of  MCL-1  when 
bound to it.42 In agreement with this, we found that 
changes in MCL-1 complexes were similar for all five 
designed molecules. Furthermore, a conformation of 
a bound MCL-1 was similar to that of the free MCL-1. 
The root mean square deviation, rmsd, between the 
free MCL-1 and the one bound to Noxa or Puma was 
measured previously to be about 1.4 Å.42 Similarly, 
we found in Deep View that the rmsd between the 
free and bound MCL-1 was about 1.6 Å for all small 
molecule complexes.
Previous  experiments  indicated  that  the  corre-
sponding MCL-1 site was about 40 Å × 20 Å when 
binding Puma or Noxa.42 Similarly, we found that the 
corresponding MCL-1 binding site was approximately 
41 Å × 18 Å when binding the designed molecules. 
The major modification in bound MCL-1 in our stud-
ies is the 5% width increase of the binding pocket 
when compared to the free MCL-1. This result agrees 
with small changes found experimentally in MCL-1 
complexes.43
Even though their overall topology was preserved, 
BCL-2  and  BCL-XL  binding  sites  experienced 
greater modifications than MCL-1 site. The rmsd val-
ues found by Deep View between the free and bound 
forms of BCL-2 and BCL-XL were about 3.0 Å and 
4.0 Å, respectively.
ABT-737 binds BCL-XL and BCL-2 within cer-
tain binding pockets.44 We found that all five designed 
molecules were able to bind the same binding pockets 
as ABT-737. These results suggest that the designed 
molecules could potentially prevent interactions of 
BCL-2 and BCL-XL with proapoptotic BH3 proteins 
in a similar fashion as ABT-737 does.
Most traditional cytotoxic agents indirectly cause 
apoptosis  by  damaging  DNA.45  However,  cancer 
cells  often  have  damaged  apoptotic  pathways  that 
allow them to avoid apoptosis.46 Current strategies 
of cancer therapy target parts of the pathways that 
are essential for cancer survival.47 The main goal is 
to sidestep damaged pathways and make the cancer 
cells susceptible to apoptosis.
Studies  aimed  at  understanding  how  ABT-737 
produces cytotoxicity in cancers45 showed that ABT-
737  stimulates  apoptosis  by  specifically  binding 
BCL-2 or BCL-XL proteins rather than by damaging 
the DNA.4,22 ABT-737 is effective in inducing apopto-
sis even at very high concentrations of its target pro-
teins. ABT-737 was found to engage the same binding 
sites of antiapoptotic proteins as cellular BH3-only 
proteins.22 Similarly, previous research showed that 
apoptosis stimulated by ABT-263 (an orally bioavail-
able agent similar to ABT-737) was the direct conse-
quence of inhibition of BCL-2 family proteins.48
Small molecules designed in this study were found 
to bind within the same binding groove as ABT-737. 
All of them share some of the structural character-
istics  of ABT-737.  In  light  of  previous  studies  on 
ABT-737,22  the  putative  mimetics  designed  here 
would be expected to stimulate apoptosis in a simi-
lar fashion by specifically binding their target BCL-2 
family proteins. If further experimental studies con-
firm this indeed to be the case, the potential of these 
new mimetics to fight cancer would be enhanced.
Acting either as a single agent or in combination 
with other chemotherapeutic agents, ABT-737 signifi-
cantly increases the cytotoxic response in certain can-
cer cells.49 Preclinical studies22 show that the highly 
specific  binding  of  ABT-737  reduces  side  effects, 
Figure 2. The MCL-1 binding groove is shown with designed small mol-
ecule C17h15n4 (red ball-and-stick). MCL-1 residues that bind noxa and 
Puma, M212, V230, V234, T247, and F251, are shown as yellow solid 
spheres. nearby MCL-1 residues are presented as purple solid spheres. 
To increase visibility of the small molecule and yellow residues, some 
MCL-1 residues are either presented as purple ball-and-stick or omitted.small molecule mimetics
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thus making it a promising candidate for clinical tri-
als. Indeed, experimental studies showed that ABT-
737  caused  negligible  undesired  effects  in  mice.4 
Similarly, small molecule ABT-702 was shown to be 
orally active, highly target specific, and non-toxic in 
mice.50
Two molecules designed in this study, C17H15N4 
and C13H10N3, were made using ABT-737 and ABT-
702  as  starting  templates.  Similarly  to  these  two 
ABT agents, the designed molecules showed affinity 
toward their target proteins. The binding propensities 
and limited cytotoxicities of ABT-737 and ABT-702, 
the oral activity of ABT-702, and predicted drug-
  likeness properties suggest that the designed mol-
ecules might likewise be promising candidates for 
clinical trials.
The  “drug-likeness”  of  the  small  molecules 
designed  here  was  estimated  using  OSIRIS  Prop-
erty Explorer40 and Molinspiration.41 OSIRIS Prop-
erty Explorer reported that no side effects (such as 
mutagenicity  or  carcinogenicity)  were  likely  for 
the  designed  molecules.  Drug-relevant  properties 
obtained by the two programs are given in Table 3. 
The number of rotatable bonds, H-bond acceptors, 
and H-bond donors were calculated by Molinspira-
tion, while the Drug-likeness and Drug Score values 
were obtained by OSIRIS. The estimates from both 
programs for the molar masses and the logP and PSA 
values were similar. Table 3 reports the values found 
by OSIRIS Property Explorer.
As can be seen from Table 3 all five of the designed 
molecules have logP # 5, −5 # logS # 1, PSA less 
than 120 Å2, molar masses less than 500 g/mol, num-
ber  of  rotatable  bonds  fewer  than  10,  number  of 
hydrogen bond donors 5 or fewer, and the number of 
hydrogen bond acceptors 10 or fewer. None of the 
designed  molecules  violate  any  of  Lipinski’s  Rule 
of Five. They all have positive drug-likeness values 
with overall drug scores between 81% and 96%. All 
five molecules form stable complexes with MCL-1, 
BCL-2, and BCL-XL proteins. They also bind at the 
same sites as cellular BH3-only proteins, as well as at 
the same BCL-2/BCL-XL site where ABT-737 binds. 
These results and previous experimental and preclini-
cal findings strongly suggest that the small molecules 
designed in this study may indeed be promising drug 
candidates.35
conclusions
Our research identified five new putative small mole-
cule mimetics that could make stable complexes with 
three  antiapoptotic  BCL-2,  BCL-XL,  and  MCL-1 
proteins.  These  results  are  novel  because,  to  our 
knowledge, there are not many, if any, small mole-
cules known to bind all three BCL-2, BCL-XL, and 
MCL-1 proteins.
The new small molecules were obtained by com-
putationally modifying experimentally known mol-
ecules. The binding energies of complexes formed 
by  the  designed  molecules  and  BCL-2,  BCL-XL, 
and  MCL-1  proteins  ranged  between  −33.5 
and −50.2 kJ/mol. Especially significant is the for-
mation of a stable complex of modified ABT-737 
with MCL-1 since the original ABT-737 does not 
interact with MCL-1. The modified ABT-702 also 
formed  stable  complexes  with  BCL-2,  BCL-XL, 
and  MCL-1.  It  is  noteworthy  that,  to  the  best  of 
our knowledge, stable complexes of ABT-702 and 
BCL-2 family proteins have not been studied previ-
ously. Drug-likeness studies performed on the five 
designed  molecules,  as  well  as  previous  experi-
mental and preclinical studies on ABT agents and 
Table 3. Drug-like properties of designed putative small molecule mimetics estimated by Molinspiration and OsIrIs   Property 
explorer. relevance and acceptable values of the listed properties are described in the text. In the table, MM stands for the 




logp logs psA MM 
(g/mol)
nrotb nOn nOHnH Drug-likeness Drug score
C18h23n4 2.69 −3.62 39.3 302.47 6 4 3 3.28 81%
C16h15n6 0.19 −2.69 80.6 296.38 4 6 5 3.30 90%
C14h15n3O 2.31 −2.41 43.9 225.29 3 3 2 1.74 85%
C17h15n4 1.95 −2.51 39.3 292.47 4 4 3 3.67 90%
C13h10n3 0.37 −1.17 31.1 213.28 1 3 2 3.63 96%Dalafave and Prisco
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BH3-only  cellular  proteins,  strongly  suggest  that 
the putative new mimetics may indeed be promising 
drug candidates.
Our findings present both possibilities and chal-
lenges for anticancer drug design. Drugs based on the 
small molecules studied here might be useful against 
cancers  that  overexpress  BCL-2,  BCL-XL,  and/or 
MCL-1   proteins. A single drug based on these mol-
ecules should cost less and cause fewer side effects 
than a combination of drugs each aimed at a single 
antiapoptotic  protein.  Molecules  designed  in  this 
work  formed  strong  bonds  with  BCL-2,  BCL-XL, 
and MCL-1 in silico. However, these molecules may 
not be easy to synthesize in a lab. Also, once synthe-
sized, they might not bind to their anticipated target 
proteins in living cells.
The usefulness of the designed molecules for anti-
cancer drug development will eventually be deter-
mined by their abilities to decrease BCL-2, BCL-XL, 
and MCL-1 expressions in living cells and to selec-
tively target cancerous versus healthy cells.
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